Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
Circulation · 2025-Jun-10 · PMID 40156843
Time to first nonfatal myocardial infarction event
Figure 1. Cumulative incidence plots of outcomes for oral semaglutide vs placebo in subgroups with or without SGLT2i use at baseline. A , Time to first occurrence of MACE. B , Time to cardiovascular death. C , Time to first nonfatal myocardial infarction event. D , Time to first nonfatal stroke event. E , Time to all-cause death. The cumulative incidence rate is calculated using the Aalen-Johansen method with noncardiovascular death ( A and B )/all-cause death ( C and D ) as a competing risk. CV indicates cardiovascular; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; and SGLT2i, sodium-glucose cotransporter-2 inhibitor
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T18:08:39+00:00 |